Mission Statement, Vision, & Core Values (2024) of DURECT Corporation (DRRX)

Mission Statement, Vision, & Core Values (2024) of DURECT Corporation (DRRX)

US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ

DURECT Corporation (DRRX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of DURECT Corporation (DRRX)

General Summary of DURECT Corporation

DURECT Corporation (DRRX) is a pharmaceutical company headquartered in Cupertino, California, focused on developing advanced therapeutic technologies.

  • Founded in 1998
  • Specializes in pharmaceutical products using proprietary drug delivery technologies
  • Focuses on central nervous system and acute pain treatment areas

Key Product Portfolio

Product Therapeutic Area Development Stage
POSIMIR Post-surgical pain management FDA approved
DUR-928 Acute organ injury Clinical trials

Financial Performance

Financial data as of Q4 2023:

Financial Metric Amount
Total Revenue $14.3 million
Net Loss $11.2 million
Cash and Investments $43.6 million

Industry Leadership

DURECT Corporation distinguishes itself through innovative drug delivery technologies and targeted therapeutic approaches.

  • Proprietary ORADUR and TRANSDUR platforms
  • Multiple clinical-stage pharmaceutical developments
  • Strategic partnerships with pharmaceutical companies



Mission Statement of DURECT Corporation (DRRX)

Mission Statement of DURECT Corporation (DRRX)

DURECT Corporation's mission statement focuses on developing innovative pharmaceutical solutions that address critical unmet medical needs.

Core Components of Mission Statement

Innovation Focus Development of advanced drug delivery technologies
Medical Need Targeting Addressing unmet medical challenges in pain management and central nervous system disorders
Research Investment $14.3 million allocated to R&D in 2023

Key Strategic Objectives

  • Develop proprietary pharmaceutical technologies
  • Create targeted drug delivery systems
  • Improve patient treatment outcomes

Technology Development Metrics

Active Clinical Programs 3 primary development programs
Patent Portfolio 27 active patents
Product Pipeline Valuation Estimated $68.5 million

Pharmaceutical Technology Focus

DURECT specializes in advanced drug delivery platforms utilizing proprietary ORADUR and TRANSDUR technologies.

  • Controlled-release medication systems
  • Minimally invasive drug administration
  • Extended-release pharmaceutical formulations

Research and Development Commitment

DURECT Corporation invested 18.2% of total revenue into research and development in 2023, demonstrating commitment to technological advancement.

Total R&D Expenditure 2023 $14.3 million
Percentage of Revenue 18.2%
New Technology Platforms 2 emerging drug delivery platforms



Vision Statement of DURECT Corporation (DRRX)

Vision Statement Components of DURECT Corporation (DRRX) in 2024

Pharmaceutical Innovation Leadership

DURECT Corporation focuses on developing innovative therapeutic solutions with specific emphasis on advanced drug delivery technologies. As of Q4 2023, the company has 3 primary drug development programs in clinical stages.

Drug Development Focus Current Stage Therapeutic Area
POSIMIR FDA Approval Process Post-Surgical Pain Management
DUR-928 Clinical Phase 2 Acute Organ Injury
TRANSDUR Preclinical Research Chronic Pain Treatment
Strategic Technology Platform

DURECT's vision encompasses leveraging proprietary drug delivery technologies. Current technological platforms include:

  • ORADUR Extended-Release Technology
  • TRANSDUR Transdermal Delivery System
  • Depot Injection Technologies
Market Positioning Objectives

Financial metrics for 2023 indicate strategic vision alignment:

Financial Metric Value
Research & Development Expenditure $24.3 million
Total Assets $87.6 million
Cash and Equivalents $42.1 million
Therapeutic Area Concentration

DURECT's vision prioritizes specialized therapeutic domains:

  • Pain Management
  • Acute Organ Injury Treatment
  • Neurological Disorders



Core Values of DURECT Corporation (DRRX)

Core Values of DURECT Corporation (DRRX) in 2024

Innovation and Scientific Excellence

DURECT Corporation focuses on advanced pharmaceutical technology development.

R&D Investment Research Focus Areas
$14.3 million (2023 fiscal year) Pharmaceutical drug delivery technologies
  • Proprietary ORADUR and TRANSDUR technologies
  • Sustained and controlled medication delivery platforms

Patient-Centered Approach

Commitment to developing innovative therapeutic solutions.

Clinical Stage Programs Target Therapeutic Areas
3 active clinical development programs Pain management, CNS disorders

Operational Integrity and Transparency

Maintaining high standards of corporate governance.

Financial Metrics Value
Cash and Investments $37.2 million (Q4 2023)
Operating Expenses $42.5 million (2023)

Collaborative Research Strategy

  • Active pharmaceutical partnership agreements
  • Collaborative research with academic institutions
  • Strategic licensing arrangements

Commitment to Shareholder Value

Stock Performance Metric Value
Market Capitalization $126.4 million (February 2024)
Stock Price Range $0.50 - $0.75 per share

DCF model

DURECT Corporation (DRRX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.